Item 2.02 Results of Operations and Financial Condition.
As part of its updated corporate investor presentation, as described below,
Spero Therapeutics, Inc. (the "Company") disclosed that its cash, cash
equivalents and marketable securities as of December 31, 2022 was approximately
$109.0 million. The following information should be considered in connection
with this preliminary result: The Company's audited, consolidated financial
statements as of December 31, 2022, are not yet available. Accordingly, the
information presented above reflects the Company's preliminary estimate, subject
to the completion of the Company's financial closing procedures and the annual
audit of its financial statements by its auditors. As a result, this preliminary
estimate may differ from the actual results that will be reflected in the
Company's audited, consolidated financial statements for the fiscal year ended
December 31, 2022 when they are completed and publicly disclosed. This
preliminary estimate may change, and that change may be material. The Company's
independent registered public accountants have not audited, reviewed or
performed any procedures with respect to such preliminary estimate and
accordingly do not express an opinion or any other form of assurance with
respect thereto.
Item 7.01. Regulation FD Disclosure.
On January 9, 2023, the Company updated its investor presentation (the "Investor
Presentation"), which the Company expects to use in connection with general
corporate presentations and will be made available on the Company's website or
distributed by the Company in hardcopy or electronic form.
A copy of the Investor Presentation is attached as Exhibit 99.1 to this Current
Report on Form 8-K (this "Current Report"). The Investor Presentation is current
as of January 9, 2023, and the Company disclaims any obligation to update the
Investor Presentation after such date.
In accordance with General Instruction B.2 on Form 8-K, except as set forth
under Item 8.01 below, the information set forth in this Item 7.01 and the
Investor Presentation is "furnished" and shall not be deemed to be "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section, nor shall such information
be deemed incorporated by reference in any filing under the Securities Exchange
Act of 1934, as amended, or the Securities Act of 1933, as amended.
Item 8.01 Other Events.
Certain portions of the Investor Presentation are attached as Exhibit 99.2 to
this Current Report and are filed with this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Investor Presentation of Spero Therapeutics, Inc. dated January 9,
2023.
99.2 Excerpts from Investor Presentation of Spero Therapeutics, Inc.
dated January 9, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses